NICE recommends Novartis Kisqali and AstraZeneca Faslodex to treat breast cancer patients

recently, the NationalHealth(http:// Institute forand Care Excellence (NICE) announced its recommendation to support Novartis Kisqali's association with AstraZeneca Faslodex for patients with hormone receptor-positive (HR-plus) and HER2-negative breast cancer patients who have previously received other treatmentsIn fact, Kisqali did not receive full access to themedical(http://nhs in the UK this time around, as NICE said it was "not clear lying that Kisqali can increase the survival time of breast cancer patients involved." "
In June 2019, Kisqali announced the results of phase 3 MONALEESA-7 clinical studyKisqali combined endocrine therapy to treat HR-HER-premenopausal breast cancer patients, at 42 months, the total survival rate (OS) in the treatment group reached 70.2%, and the control group's OS was only 46.0%Although existing clinicaltrial strial(http://evidence suggests that the Kisqali combination significantly improves disease progression in patients with previously untreated advanced diseases and in patients who have received endocrine therapy as a whole compared to Faslodex aloneHowever, due to the uncertainty of clinical evidence and the fact that thedrug (http:// well above NICE's generally considered cost-effective estimate of the use of acceptable NHS resources, the regulator did not consider it possible to recommend the full integration of Kisqali's combination with Faslodex into the health care system 　　Currently, NICE approves the drug in the form of patients in the UK who have access to treatment through the Cancer Drugs Fund, which requires their own application NICE imposed similar regulatory restrictions on Lilly Verzenio in April 　　Currently, three CDK4/6 inhibitors have been approved for listing worldwide, with a market size of $4.608 billion in 2018, with Pfizer Ibrance accounting for nearly 90 percent of the market 　　Lilly Verzenio has been in the market for six months than Novartis Kisqali, but the market is doing better, already outperforming Kisqali in second place This positive recommendation from Kisqali to NICE will undoubtedly help with the growth of its performance